Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provided informed consent (emergency consent according to local regulations where approved)~2. Age 18 to 75 years (inclusive)~3. Admitted to an intensive care unit~4. Treatment with High Flow Nasal Oxygen, non-invasive ventilation or invasive mechanical ventilation for acute respiratory failure caused by COVID-19 for less than 48 hours~5. A PaO2:FiO2 ratio of \<200mmHg (\<26.7kPa) with a FiO2 ≥0.6~6. Confirmed laboratory diagnosis of COVID-19 within 7 days of meeting screening criteria~Exclusion Criteria:~1. Known pregnancy (positive urine or serum pregnancy test)~2. Ongoing treatment with an immunomodulatory agent not included in the standard of care for COVID-19 (including participation in clinical trials of such agents).~3. Body mass index (BMI) ≥ 40 kg/m2or weight ≥ 130 kg~4. Anticipated transfer to another hospital, which is not a study site within 72 hours~5. Expected to die within 6 months of treatment due to underlying chronic disease~6. Limitations of care in place during current hospital admission~   -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- nangibotide (Type: EXPERIMENTAL): Continuous infusion of experimental agent for up to 120 hours
- placebo (Type: PLACEBO_COMPARATOR): Continuous infusion of matched placebo for up to 120 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).